Bradley Foster & Sargent Inc. CT Has $27.96 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Bradley Foster & Sargent Inc. CT decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 31.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 142,260 shares of the medical research company’s stock after selling 65,672 shares during the period. Bradley Foster & Sargent Inc. CT owned about 0.08% of IQVIA worth $27,956,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. FMR LLC boosted its holdings in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in IQVIA during the 3rd quarter worth approximately $147,683,000. JPMorgan Chase & Co. boosted its stake in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the period. Nordea Investment Management AB grew its holdings in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after buying an additional 250,458 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Price Performance

IQV stock opened at $194.01 on Friday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $34.16 billion, a P/E ratio of 25.87, a PEG ratio of 2.01 and a beta of 1.48. The company has a fifty day moving average price of $199.73 and a 200-day moving average price of $216.79. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.86 EPS for the current year.

Insiders Place Their Bets

In related news, Director John G. Danhakl bought 1,275 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on IQV. Morgan Stanley raised their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. The Goldman Sachs Group lowered their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Stifel Nicolaus lowered their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, JPMorgan Chase & Co. cut their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.